Skip to main content
Yvonne Efebera, MD, Hematology, Columbus, OH

YvonneA.EfeberaMDMPH

Hematology Columbus, OH

Associate Professor, Dept of Internal Medicine, Division of Hematology, The Ohio State University.

Dr. Efebera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Efebera's full profile

Already have an account?

  • Office

    500 Thomas Ln
    Columbus, OH 43214
    Phone+1 614-566-2500
    Fax+1 614-293-4812

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
  • Pennsylvania State University College of Medicine
    Pennsylvania State University College of MedicineClass of 1998

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2000 - 2025
  • TX State Medical License
    TX State Medical License 2008 - 2022
  • MA State Medical License
    MA State Medical License 2004 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
    Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
    Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • OhioHealth's New Blood and Marrow Transplant Program Is Open
    OhioHealth's New Blood and Marrow Transplant Program Is OpenApril 5th, 2022
  • What Is the Optimal Duration of Maintenance in Myeloma?
    What Is the Optimal Duration of Maintenance in Myeloma?October 8th, 2019
  • Late-Breaking Abstracts Session
    Late-Breaking Abstracts SessionDecember 6th, 2016
  • Join now to see all

Professional Memberships